Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more
Market Cap & Net Worth: Transgene SA (TRGNF)
Transgene SA (PINK:TRGNF) has a market capitalization of $191.73 Million ($191.73 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #20407 globally and #7411 in its home market, demonstrating a -55.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Transgene SA's stock price $0.70 by its total outstanding shares 273905710 (273.91 Million).
Transgene SA Market Cap History: 2015 to 2025
Transgene SA's market capitalization history from 2015 to 2025. Data shows change from $753.24 Million to $191.73 Million (-13.72% CAGR).
Transgene SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Transgene SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
68.55x
Transgene SA's market cap is 68.55 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $753.24 Million | $1.47 Million | -$46.37 Million | 514.16x | N/A |
| 2016 | $753.24 Million | $2.35 Million | -$25.21 Million | 321.07x | N/A |
| 2017 | $870.61 Million | $2.10 Million | -$32.27 Million | 414.77x | N/A |
| 2018 | $838.56 Million | $1.33 Million | $8.03 Million | 628.14x | 104.48x |
| 2019 | $495.77 Million | $13.30 Million | -$18.80 Million | 37.29x | N/A |
| 2020 | $550.55 Million | $2.98 Million | -$18.45 Million | 184.69x | N/A |
| 2021 | $832.67 Million | $9.99 Million | -$20.00 Million | 83.33x | N/A |
| 2022 | $2.74 Million | $3.13 Million | -$32.81 Million | 0.88x | N/A |
| 2023 | $443.73 Million | $7.90 Million | -$22.33 Million | 56.17x | N/A |
| 2024 | $435.51 Million | $6.35 Million | -$33.97 Million | 68.55x | N/A |
Competitor Companies of TRGNF by Market Capitalization
Companies near Transgene SA in the global market cap rankings as of March 18, 2026.
Key companies related to Transgene SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Transgene SA Historical Marketcap From 2015 to 2025
Between 2015 and today, Transgene SA's market cap moved from $753.24 Million to $ 191.73 Million, with a yearly change of -13.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $191.73 Million | -55.97% |
| 2024 | $435.51 Million | -1.85% |
| 2023 | $443.73 Million | +16100.00% |
| 2022 | $2.74 Million | -99.67% |
| 2021 | $832.67 Million | +51.24% |
| 2020 | $550.55 Million | +11.05% |
| 2019 | $495.77 Million | -40.88% |
| 2018 | $838.56 Million | -3.68% |
| 2017 | $870.61 Million | +15.58% |
| 2016 | $753.24 Million | 0.00% |
| 2015 | $753.24 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Transgene SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $191.73 Million USD |
| MoneyControl | $191.73 Million USD |
| MarketWatch | $191.73 Million USD |
| marketcap.company | $191.73 Million USD |
| Reuters | $191.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.